Pozen's Lead Stomach-Friendly Aspirin Positive in Phase III
By Catherine Shaffer
Friday, March 23, 2012
Relief may be on the way for cardiac patients who can't tolerate aspirin. Pozen Inc., of Chapel Hill, N.C., reported positive results from two Phase III pivotal trials showing that treatment with PA32540, a formulation of aspirin combined with the proton pump inhibitor omeprazole, led to a significant reduction in gastric ulcers compared to enteric-coated aspirin.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.